| Code | CSB-RA008625MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to rHIgM22, targeting fibroblast growth factor 2 (FGF2), also known as basic FGF. FGF2 is a heparin-binding growth factor that plays critical roles in angiogenesis, cell proliferation, differentiation, and tissue repair. It signals primarily through FGF receptors to activate downstream pathways including MAPK and PI3K-AKT cascades. FGF2 is implicated in various pathological conditions including cancer progression, where it promotes tumor angiogenesis and metastasis, as well as in cardiovascular disease, wound healing disorders, and neurodegenerative conditions.
The reference antibody rHIgM22 has been utilized in research investigating FGF2-mediated signaling pathways and its role in disease pathogenesis. This biosimilar antibody provides researchers with a reliable tool for studying FGF2 function in cellular processes, examining its involvement in tumor microenvironments, and exploring potential therapeutic interventions targeting FGF2-dependent mechanisms. The antibody serves as a valuable reagent for investigating growth factor biology and developmental processes.
There are currently no reviews for this product.